Axicabtagene ciloleucel: all 28 studies that test it

Page 1 of 1. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.

• CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.RecruitingNCT07538635Phase 2
• Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell LymphomaRecruitingNCT07254754Phase 2
• Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T CellsRecruitingNCT07042438Phase 2
• Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell LymphomaNot yet recruitingNCT06935136Not applicable
• Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular LymphomaRecruitingNCT06826118Phase 2
• Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell LymphomaRecruitingNCT06609304Phase 4
• A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell LymphomaRecruitingNCT06213311Phase 2
• A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular LymphomaRecruitingNCT06043323Phase 2
• Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-CelRecruitingNCT05794958Phase 1
• Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT05633615Phase 2
• Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin LymphomaRecruitingNCT05077527Phase 1
• Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient SettingCompletedNCT05108805Phase 4Results posted
• Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell TherapyCompletedNCT05075603Phase 1Results posted
• Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell LymphomaTerminatedNCT04314843Phase 1Results posted
• Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell LymphomaCompletedNCT04002401Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell LymphomaCompletedNCT03761056Phase 2Results posted
• Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell LymphomaTerminatedNCT03704298Phase 1Results posted
• MT2017-45: CAR-T Cell Therapy for Heme MalignanciesActive, not recruitingNCT03642626Phase 2Results posted
• Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell LymphomaCompletedNCT03391466Phase 3Results posted
• A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin LymphomaCompletedNCT03105336Phase 2Results posted
• Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02926833Phase 1/2Results posted
• Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line TherapyActive, not recruitingNCT07479797Phase 3
• Axi-cel Retreatment in Relapsed/Refractory LBCLStatus unknownNCT05800067Not applicable
• Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell LymphomaActive, not recruitingNCT05605899Phase 3
• Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell LymphomaCompletedNCT05459571Phase 2
• Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular LymphomaActive, not recruitingNCT05371093Phase 3
• Axi-cel in CNS LymphomaActive, not recruitingNCT04608487Phase 1
• Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell TransplantationActive, not recruitingNCT04531046Phase 2

← Axicabtagene ciloleucel overview